Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. insiders are currently net sellers of ZNTL stock, showing neutral sentiment over the past 90 days. Total sales of $122.2M outpace purchases of $122.1M, creating a net outflow of $154.0K.

Zentalis Pharmaceuticals, Inc. has 25 active insiders who have filed SEC Form 4 transactions in the past 90 days. Capital Management Company, Lp Matrix (Executive) leads with 1 transactions totaling $107.9M. Anthony Y. Sun (Executive) follows with 118 transactions worth $32.8M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Zentalis Pharmaceuticals, Inc.'s current score of 50/100 indicates neutral insider sentiment. Scores between 40-60 represent neutral or mixed activity. With $122.1M in purchases and $122.2M in sales, no strong directional conviction is evident.

The most recent insider transaction occurred on Feb 10, 2026, when Vultaggio Vincent (PAO and PFO) disposed of 6,894 shares at $2.42 per share for $16.7K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, ZNTL insider trading sentiment is currently neutral with an Alignment Score of 50/100. The balanced activity—$122.1M bought vs $122.2M sold—suggests no strong consensus among insiders.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Zentalis Pharmaceuticals, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ZNTL, we track all Form 4 filings—currently showing 550 transactions from 25 insiders over 90 days.

A 10b5-1 plan allows Zentalis Pharmaceuticals, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At ZNTL, approximately 6% of recent transactions are 10b5-1 trades. The remaining 94% are discretionary trades, which may carry more informational value.

You can monitor Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 25 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Zentalis Pharmaceuticals, Inc.'s current score of 50/100 indicates neutral sentiment with balanced buying and selling activity. This is calculated from $122.1M in purchases versus $122.2M in sales over 90 days, resulting in a net flow of -$154.0K.

SEC Form 4 filings are mandatory reports that Zentalis Pharmaceuticals, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ZNTL, the most common type is "A" with 25 occurrences. The most recent Form 4 was filed on Feb 10, 2026 by Vultaggio Vincent.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Zentalis Pharmaceuticals, Inc., approximately 6% of recent transactions are executed under 10b5-1 plans, while 94% appear to be discretionary trades. The low percentage means most insider activity at ZNTL represents discretionary decisions with more informational value.